The Mentoring Round | David Snyder, CFO, Coya Therapeutics
Inside The Mentoring Round, CFO David Snyder of Coya Therapeutics stresses that biotech companies must not get sidetracked by short-term valuations or minor gains but should focus on the bigger picture of achieving substantial market capitalization. This perspective is grounded in the understanding that success in biotech often hinges on the ability to finance a […]
968: From the Investor’s Point of View | David Snyder, CFO, Coya Therapeutics
At Moderna, A CFO Vows To De-risk R&D As mRNA Tech Promises To Shorten Success Path
This article first appeared on Forbes.com Speed to market has always been critical in the life sciences industry. Companies that bring products to market quickly and efficiently are better positioned to succeed and improve patient outcomes. Or so the industry wisdom goes. For Moderna, the covid wunderkind that captured almost $40 billion in sales over the […]
963: How a Biotech Disrupter Is De-risking R&D | Jamey Mock, CFO, Moderna
934: You’ll Figure It Out | Svai Sanford, CFO, Rani Therapeutics
Biotech’s Quest for Growth | Erin Golgan Sensei Bio
CFO GUEST: Erin Colgan of Sensei Bio
920: When Leadership Calls | Erin Colgan, CFO, Sensei Bio
Why the Journey Matters | Galit Yaakobovitz, CFO, AmyriAD
CFO GUEST: Galit Yaakobovitz of AmyriAD Yaakobovitz: I think it’s also a part of my personality. Uh, I like the journey, and I’ll tell you about my personal life later, but, uh, I, I like to enjoy the journey. And if I’m, uh, in a certain path and I enjoy it, I don’t really care […]